BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22098610)

  • 1. Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.
    Ishizu Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1112-6. PubMed ID: 22098610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
    Sikorska K; Stalke P; Izycka-Swieszewska E; Romanowski T; Bielawski KP
    Med Sci Monit; 2010 Mar; 16(3):CR137-143. PubMed ID: 20190684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C.
    Carneiro MV; Souza FF; Teixeira AC; Figueiredo JF; Villanova MG; Secaf M; Passos AD; Ramalho LN; Carneiro FP; Zucoloto S; Candolo Martinelli AL
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1204-10. PubMed ID: 20555268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The H63D mutation of the hemochromatosis gene is associated with sustained virological response in chronic hepatitis C patients treated with interferon-based therapy: a meta-analysis.
    Li SH; Zhao H; Ren YY; Liu YZ; Song G; Ding P; Ding YP; Wang GQ
    Tohoku J Exp Med; 2012 Apr; 226(4):293-9. PubMed ID: 22499121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C.
    Lebray P; Zylberberg H; Hue S; Poulet B; Carnot F; Martin S; Chretien Y; Pol S; Caillat-Zuckman S; Bréchot C; Nalpas B
    J Viral Hepat; 2004 Mar; 11(2):175-82. PubMed ID: 14996353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
    Guzmán-Fulgencio M; Berenguer J; Rallón N; Fernández-Rodríguez A; Miralles P; Soriano V; Jiménez-Sousa MA; Cosín J; Medrano J; García-Álvarez M; López JC; Benito JM; Resino S
    AIDS; 2013 May; 27(8):1231-8. PubMed ID: 23811951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
    Bonkovsky HL; Naishadham D; Lambrecht RW; Chung RT; Hoefs JC; Nash SR; Rogers TE; Banner BF; Sterling RK; Donovan JA; Fontana RJ; Di Bisceglie AM; Ghany MG; Morishima C;
    Gastroenterology; 2006 Nov; 131(5):1440-51. PubMed ID: 17101320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.
    Gehrke SG; Stremmel W; Mathes I; Riedel HD; Bents K; Kallinowski B
    J Mol Med (Berl); 2003 Dec; 81(12):780-7. PubMed ID: 14557859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
    Fujita N; Sugimoto R; Urawa N; Araki J; Mifuji R; Yamamoto M; Horiike S; Tanaka H; Iwasa M; Kobayashi Y; Adachi Y; Kaito M
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1886-93. PubMed ID: 17914965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
    Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
    New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of HFE gene polymorphism on sustained virological response in patients with chronic hepatitis C and elevated serum ferritin.
    Coelho-Borges S; Cheinquer H; Wolff FH; Cheinquer N; Krug L; Ashton-Prolla P
    Arq Gastroenterol; 2012; 49(1):9-13. PubMed ID: 22481680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload.
    Coelho-Borges S; Cheinquer H; Cheinquer N; Krug L; Ashton-Prolla P
    Am J Gastroenterol; 2002 Jun; 97(6):1570-2. PubMed ID: 12094895
    [No Abstract]   [Full Text] [Related]  

  • 15. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemochromatosis gene mutations: prevalence and effects on pegylated-interferon and ribavirin therapy response in chronic hepatitis C in sardinia.
    Sini M; Sorbello O; Civolani A; Demelia L
    J Clin Exp Hepatol; 2012 Sep; 2(3):211-7. PubMed ID: 25755436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection.
    Distante S; Bjøro K; Hellum KB; Myrvang B; Berg JP; Skaug K; Raknerud N; Bell H
    Liver; 2002 Jun; 22(3):269-75. PubMed ID: 12100578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of mutation of the HFE gene on the progression of chronic viral hepatitis B and C in Moroccan patients.
    Ezzikouri S; Rebbani K; Mostafa A; El Feydi AE; Afifi R; Brahim I; Kitab B; Benazzouz M; Kandil M; Nadifi S; Pineau P; Benjelloun S
    J Med Virol; 2011 Dec; 83(12):2096-102. PubMed ID: 22012716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan.
    Lin TJ; Lin CL; Wang CS; Liu SO; Liao LY
    World J Gastroenterol; 2005 Jul; 11(25):3905-8. PubMed ID: 15991291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.